| scholarly article | Q13442814 |
| P8150 | COVIDWHO ID | covidwho-1966 |
| P6179 | Dimensions Publication ID | 1125089278 |
| P356 | DOI | 10.1038/S41564-020-0688-Y |
| P953 | full work available at URL | https://www.nature.com/articles/s41564-020-0688-y |
| P932 | PMC publication ID | 7095430 |
| P698 | PubMed publication ID | 32094589 |
| P8299 | Semantic Scholar corpus ID | 211253784 |
| P50 | author | Michael Letko | Q89866687 |
| Vincent J. Munster | Q37375884 | ||
| Andrea Marzi | Q50285805 | ||
| P2860 | cites work | A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry | Q24306622 |
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats | Q24536078 | ||
| Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion | Q27302420 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| Bats are natural reservoirs of SARS-like coronaviruses | Q28274751 | ||
| Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor | Q30219701 | ||
| Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. | Q30354466 | ||
| Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus | Q30400728 | ||
| Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. | Q30432156 | ||
| Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection | Q30447031 | ||
| Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro | Q33516234 | ||
| Structure, Function, and Evolution of Coronavirus Spike Proteins | Q33760875 | ||
| Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus | Q34120263 | ||
| Structure of SARS coronavirus spike receptor-binding domain complexed with receptor | Q34451350 | ||
| Molecular diversity of coronaviruses in bats. | Q34519162 | ||
| Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy | Q34632946 | ||
| Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels | Q34641515 | ||
| Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses | Q34983662 | ||
| Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease | Q35599437 | ||
| Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis | Q35735214 | ||
| A pneumonia outbreak associated with a new coronavirus of probable bat origin | Q84367633 | ||
| Rousettus aegyptiacus Bats Do Not Support Productive Nipah Virus Replication | Q91089778 | ||
| Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection | Q91697408 | ||
| Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus | Q93037598 | ||
| Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus | Q35913859 | ||
| SARS-CoV infection in a restaurant from palm civet | Q36009490 | ||
| RNA recombination in a coronavirus: recombination between viral genomic RNA and transfected RNA fragments | Q36702356 | ||
| A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence | Q36702376 | ||
| A system for functional analysis of Ebola virus glycoprotein | Q36831630 | ||
| Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice | Q36986417 | ||
| Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites | Q37138587 | ||
| Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission | Q37631303 | ||
| Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus | Q46251133 | ||
| Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. | Q51660929 | ||
| Adaptive Evolution of MERS-CoV to Species Variation in DPP4 | Q56557651 | ||
| Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission | Q57477156 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiotensin I converting enzyme 2 | Q301630 |
| viral entry into host cell | Q4118894 | ||
| Betacoronavirus | Q16532287 | ||
| COVID-19 | Q84263196 | ||
| Coronavirus spike protein | Q108250944 | ||
| virus receptors | Q66053321 | ||
| SARS-CoV-2 | Q82069695 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 562-569 | |
| P577 | publication date | 2020-02-24 | |
| P1433 | published in | Nature Microbiology | Q23022567 |
| P1476 | title | Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses | |
| P478 | volume | 5 |
| Q92102749 | 2019 Novel coronavirus (COVID-19) overview |
| Q88977483 | A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein |
| Q104068995 | A Study of Potential SARS-CoV-2 Antiviral Drugs and Preliminary Research of Their Molecular Mechanism, Based on Anti-SARS-CoV Drug Screening and Molecular Dynamics Simulation |
| Q94474211 | A novel COVID-19 and its effects on cardiovascular disease |
| Q95628520 | A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition |
| Q91800366 | A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |
| Q102210989 | A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots |
| Q88458126 | A serological assay to detect SARS-CoV-2 seroconversion in humans |
| Q94600837 | A serological assay to detect SARS-CoV-2 seroconversion in humans |
| Q110176615 | A structural view of the SARS-CoV-2 virus and its assembly |
| Q100533622 | A systematic review of SARS-CoV-2 vaccine candidates |
| Q91994894 | Acute kidney injury in SARS-CoV-2 infected patients |
| Q98615178 | Aerosol transmission of SARS-CoV-2? Evidence, prevention and control |
| Q96223294 | Age-related expression of SARS-CoV-2 priming protease TMPRSS2 in the developing lung |
| Q92136385 | Age-related rhesus macaque models of COVID-19 |
| Q110566478 | Alpha-Soluble NSF Attachment Protein Prevents the Cleavage of the SARS-CoV-2 Spike Protein by Functioning as an Interferon-Upregulated Furin Inhibitor |
| Q99247023 | Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes |
| Q96680187 | An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening |
| Q104523240 | Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine candidate |
| Q98611638 | Animal and translational models of SARS-CoV-2 infection and COVID-19 |
| Q89975869 | Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63 |
| Q98906913 | Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report |
| Q90331626 | Back to the spring of Wuhan: facts and hope of COVID-19 outbreak |
| Q96302798 | Bat-borne virus diversity, spillover and emergence |
| Q111291784 | Betacoronavirus Assembly: Clues and Perspectives for Elucidating SARS-CoV-2 Particle Formation and Egress |
| Q99402395 | Beyond Infection: Integrating Competence into Reservoir Host Prediction |
| Q99552103 | Bibliometric analysis of global scientific research on Coronavirus (COVID-19) |
| Q102129687 | Bilateral Renal Artery Thrombosis in a Patient With COVID-19 |
| Q94555197 | Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2 |
| Q106638260 | COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms |
| Q90491402 | COVID-19 Infection: Implications for Perioperative and Critical Care Physicians |
| Q110566847 | COVID-19 Transcriptomic Atlas: A Comprehensive Analysis of COVID-19 Related Transcriptomics Datasets |
| Q98575387 | COVID-19 and COPD |
| Q93222491 | COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |
| Q91828431 | COVID-19 and diabetes: Knowledge in progress |
| Q98466678 | COVID-19 and the Kidneys: An Update |
| Q93160359 | COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country |
| Q88978176 | COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning |
| Q94446883 | COVID-19 pandemic - A focused review for clinicians |
| Q93182046 | COVID-19 pathophysiology: A review |
| Q104135098 | COVID-19: neonatal-perinatal perspectives |
| Q109071931 | COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms |
| Q94529598 | Can N95 Respirators Be Reused after Disinfection? How Many Times? |
| Q95619513 | Can N95 respirators be reused after disinfection? And for how many times? |
| Q91859258 | Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19) |
| Q94589965 | Cell entry mechanisms of SARS-CoV-2 |
| Q98157765 | Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein |
| Q100465248 | Characteristics of SARS-CoV-2 and COVID-19 |
| Q99574943 | Characteristics of immune cells and cytokines in patients with coronavirus disease 2019 in Guangzhou, China |
| Q95626601 | Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual |
| Q97529052 | Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms: An Analysis of Seven Patients in China |
| Q94471997 | Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China |
| Q97588508 | Coagulopathy in COVID-19: Focus on vascular thrombotic events |
| Q93239623 | Combination of Biodata Mining and Computational Modelling in Identification and Characterization of ORF1ab Polyprotein of SARS-CoV-2 Isolated from Oronasopharynx of an Iranian Patient |
| Q94561606 | Commentary: Origin and evolution of pathogenic coronaviruses |
| Q110653032 | Comparative Host Interactomes of the SARS-CoV-2 Nonstructural Protein 3 and Human Coronavirus Homologs |
| Q99552342 | Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition |
| Q99591157 | Complex Immunometabolic Profiling Reveals the Activation of Cellular Immunity and Biliary Lesions in Patients with Severe COVID-19 |
| Q89890130 | Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2 |
| Q92002264 | Coronavirus Disease: A Review of a New Threat to Public Health |
| Q101051357 | Coronavirus biology and replication: implications for SARS-CoV-2 |
| Q99578834 | Coronavirus disease-19 spread in the Eastern Mediterranean Region, updates and prediction of disease progression in Kingdom of Saudi Arabia, Iran, and Pakistan |
| Q91953835 | Coronaviruses and SARS-COV-2 |
| Q89741503 | Coronaviruses: a paradigm of new emerging zoonotic diseases |
| Q98772723 | Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology |
| Q95300582 | Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody |
| Q98467307 | Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity |
| Q88977486 | Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections |
| Q95275874 | Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections |
| Q91908460 | D2EA: Depict the Epidemic Picture of COVID-19 |
| Q107074014 | DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist |
| Q107377319 | DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist |
| Q98720898 | Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding |
| Q97074400 | Delving deep into the structural aspects of a furin cleavage site inserted into the spike protein of SARS-CoV-2: A structural biophysical perspective |
| Q99631290 | Development and effectiveness of Pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro |
| Q100750398 | Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2 |
| Q97536520 | Diabetes and Novel Coronavirus Infection: Implications for Treatment |
| Q104479781 | Does the RAAS play a role in loss of taste and smell during COVID-19 infections? |
| Q107033036 | Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2 |
| Q107033464 | Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2 |
| Q98577397 | Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 |
| Q98626411 | Emerging strategies on in silico drug development against COVID-19: challenges and opportunities |
| Q97524597 | Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development |
| Q91601280 | Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19) |
| Q107162147 | Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail |
| Q95602120 | Establishment of an African green monkey model for COVID-19 |
| Q102379526 | Establishment of an African green monkey model for COVID-19 and protection against re-infection |
| Q94550021 | Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency |
| Q99717913 | Expression of ACE2 in airways: implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases |
| Q100750268 | Expression of SARS-CoV-2 entry factors in lung epithelial stem cells and its potential implications for COVID-19 |
| Q95616882 | Extra-respiratory manifestations of COVID-19 |
| Q107392235 | Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies |
| Q111741723 | Factors Responsible for Emergence of Novel Viruses: An emphasis on SARS-CoV-2 |
| Q99593526 | Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein |
| Q100387963 | Functional genomic screens identify human host factors for SARS-CoV-2 and common cold coronaviruses |
| Q104470312 | Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses |
| Q100535021 | Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks |
| Q101222451 | Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection |
| Q99637399 | Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection |
| Q112033502 | Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2 |
| Q107466751 | Glycosylation of SARS-CoV-2: structural and functional insights |
| Q98664283 | Growth, detection, quantification, and inactivation of SARS-CoV-2 |
| Q99201268 | How can nanotechnology help to combat COVID-19? Opportunities and urgent need |
| Q107349011 | How glycobiology can help us treat and beat the COVID-19 pandemic |
| Q104486623 | Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology |
| Q90502868 | Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia |
| Q98464576 | Immune Response and COVID-19: A mirror image of Sepsis |
| Q96953625 | Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 |
| Q97530822 | Immune-mediated approaches against COVID-19 |
| Q99202166 | Improved binding of SARS-CoV-2 Envelope protein to tight junction-associated PALS1 could play a key role in COVID-19 pathogenesis |
| Q93223318 | Incidence of coronavirus disease (COVID-19) and countries affected by malarial infections |
| Q107202345 | Infection and transmission of SARS-CoV-2 depends on heparan sulfate proteoglycans |
| Q93221320 | Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 |
| Q98727123 | Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies |
| Q108502833 | Interleukin-1RA Mitigates SARS-CoV-2–Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice |
| Q99633063 | Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)? |
| Q99413341 | Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study |
| Q93232009 | Letter: The Risk of COVID-19 Infection During Neurosurgical Procedures: A Review of Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2) Modes of Transmission and Proposed Neurosurgery-Specific Measures for Mitigation |
| Q97562331 | Long-term infection of SARS-CoV-2 changed the body's immune status |
| Q98829888 | Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy |
| Q88973760 | Machine intelligence design of 2019-nCoV drugs |
| Q93207285 | Machine learning using intrinsic genomic signatures for rapid classification of novel pathogens: COVID-19 case study |
| Q101166587 | Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models |
| Q96223358 | Modeling and Simulation of a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane |
| Q91766723 | More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19 |
| Q106626599 | Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins |
| Q107349084 | Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins |
| Q99240136 | Nanomedicine strategies to target coronavirus |
| Q98164769 | Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients |
| Q94490808 | Natural product-derived phytochemicals as potential agents against coronaviruses: A review |
| Q98181541 | Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 |
| Q99207882 | Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19 |
| Q96647306 | Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19 |
| Q97540853 | Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link? |
| Q93193811 | Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |
| Q104473782 | Optimized pseudotyping conditions for the SARS-COV2 Spike glycoprotein |
| Q91775127 | Pediatric Endocrinology in the Time of the COVID-19 Pandemic |
| Q93190302 | Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |
| Q98571334 | Pharmacological treatments of COVID-19 |
| Q123253382 | Phosphatidylserine receptors enhance SARS-CoV-2 infection |
| Q93153199 | Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop |
| Q91876180 | Potential neurological symptoms of COVID-19 |
| Q97067433 | Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience |
| Q99406885 | Potential use of polyphenols in the battle against COVID-19 |
| Q109922312 | Prediction of Non-canonical Routes for SARS-CoV-2 Infection in Human Placenta Cells |
| Q100535027 | Preferential recognition and antagonism of SARS-CoV-2 spike glycoprotein binding to 3- O -sulfated heparan sulfate |
| Q90723648 | Prevalence and impact of diabetes among people infected with SARS-CoV-2 |
| Q92118157 | Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis |
| Q94674310 | Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature |
| Q98730822 | Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development |
| Q111271438 | Proteases and variants: context matters for SARS-CoV-2 entry assays |
| Q88973795 | Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1 |
| Q107133304 | Proteomics-based Insights into the SARS-CoV-2 Mediated COVID-19 Pandemic: A Review of the First Year of Research |
| Q89846214 | Puzzle of highly pathogenic human coronaviruses (2019-nCoV) |
| Q98577501 | Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera |
| Q99597106 | Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment |
| Q99555141 | Quasi-species nature and differential gene expression of severe acute respiratory syndrome coronavirus 2 and phylogenetic analysis of a novel Iranian strain |
| Q99417440 | RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges |
| Q109919888 | Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2 |
| Q96129339 | Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 |
| Q101213871 | Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City |
| Q94674303 | Research Progress of Drug Treatment in Novel Coronavirus Pneumonia |
| Q88046426 | Return of the Coronavirus: 2019-nCoV |
| Q95628676 | Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 |
| Q97074100 | Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS |
| Q108834038 | S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity |
| Q110492151 | SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells |
| Q94938805 | SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues |
| Q97426438 | SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain |
| Q91662248 | SARS-CoV-2 Vaccines: Status Report |
| Q93228609 | SARS-CoV-2 and DPP4 inhibition: is it time to pray for Janus Bifrons? |
| Q107076476 | SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation |
| Q97540652 | SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects |
| Q107071807 | SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies |
| Q97653016 | SARS-CoV-2 genomic variations associated with mortality rate of COVID-19 |
| Q99371011 | SARS-CoV-2 host tropism: an in silico analysis of the main cellular factors |
| Q98665285 | SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function |
| Q99552323 | SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike |
| Q98467318 | SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents |
| Q107473200 | SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis |
| Q88976393 | SARS-CoV-2 is sensitive to type I interferon pretreatment |
| Q111620849 | SARS-CoV-2 spike protein–induced cell fusion activates the cGAS-STING pathway and the interferon response |
| Q110178920 | SARS-CoV-2 uses metabotropic glutamate receptor subtype 2 as an internalization factor to infect cells |
| Q99614554 | SARS-CoV-2 vaccines in development |
| Q93198858 | Salivary diagnostics in COVID-19: Future research implications |
| Q99712193 | Single-Cell RNA-seq Identifies Cell Subsets in Human Placenta That Highly Expresses Factors Driving Pathogenesis of SARS-CoV-2 |
| Q88979282 | Site-specific analysis of the SARS-CoV-2 glycan shield |
| Q94520441 | Site-specific glycan analysis of the SARS-CoV-2 spike |
| Q95643979 | Sodium status and kidney involvement during COVID-19 infection |
| Q92081855 | Specific ACE2 Expression in Small Intestinal Enterocytes may Cause Gastrointestinal Symptoms and Injury after 2019-nCoV Infection |
| Q104438055 | Spike Protein of SARS-CoV-2 Activates Macrophages and Contributes to Induction of Acute Lung Inflammations in Mice |
| Q90574300 | Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection |
| Q98196753 | Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 |
| Q101038504 | Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation |
| Q90738246 | Structural basis of receptor recognition by SARS-CoV-2 |
| Q90738260 | Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor |
| Q87973551 | Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein |
| Q98205399 | Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation |
| Q104503876 | Subtle influence of ACE2 glycan processing on SARS-CoV-2 recognition |
| Q91737660 | Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2 |
| Q95297164 | Symptom profiles and risk factors for hospitalization in patients with SARS-CoV-2 and COVID-19: A Large Cohort from South America |
| Q100534347 | Syncytia formation by SARS-CoV-2 infected cells |
| Q108396431 | Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell |
| Q95602650 | TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes |
| Q94670006 | TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes |
| Q107073292 | Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis |
| Q94484146 | The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much? |
| Q94679998 | The Challenges of Vaccine Development against a New Virus during a Pandemic |
| Q98171290 | The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity |
| Q98165190 | The Impact of SARS-Cov-2 Virus Infection on the Endocrine System |
| Q94673612 | The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike |
| Q98224516 | The Post-Lockdown Era: What Is Next in Italy? |
| Q97550289 | The Relationship between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China |
| Q94667797 | The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor? |
| Q106626821 | The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins |
| Q89198787 | The SARS-CoV-2 outbreak from a one health perspective |
| Q91977604 | The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments |
| Q89841223 | The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future |
| Q110864776 | The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione |
| Q90310442 | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status |
| Q87830056 | The proximal origin of SARS-CoV-2 |
| Q94581334 | The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19? |
| Q88977509 | The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2 |
| Q111271260 | The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling |
| Q99581970 | Therapeutic Options for COVID-19: A Review |
| Q90744904 | Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective |
| Q101451942 | Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus |
| Q91826142 | Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed |
| Q96126863 | Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients |
| Q99557054 | Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV |
| Q95308075 | Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing |
| Q94683922 | Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients |
| Q96027337 | Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens |
| Q107341853 | Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review |
| Q93199790 | Understanding the Mosaic of COVID-19: A Review of the Ongoing Crisis |
| Q104452150 | Unexpected free fatty acid binding pocket in the cryo-EM structure of SARS-CoV-2 spike protein |
| Q97438274 | Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus |
| Q97070966 | Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
| Q94960143 | Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target |
| Q90626655 | Using the spike protein feature to predict infection risk and monitor the evolutionary dynamic of coronavirus |
| Q99604172 | Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system |
| Q107404382 | Variations in Orf3a protein of SARS-CoV-2 alter its structure and function |
| Q96768876 | Well-controlled vs Poorly-controlled Diabetes in Patients with COVID-19: Are There Any Differences in Outcomes and Imaging Findings? |
Search more.